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Clinics and pathology 
Disease 
Myeloid lineage, found in 1 myelodysplastic syndrome 
(MDS) and 1 Acute Myeloid Leukemia (AML). 
Phenotype / cell stem origin 
MDS-RA and M1 AML by FAB criteria, a primitive 
myeloid progenitor is likely to be involved. 
Etiology 
No known prior exposure. 
Epidemiology 
Only 2 cases to date, a 69 year old female and a 31 year 
old male, sex ratio 1M/1F. 
Clinics 
Elevated WBC (68x109l), 93% blasts in blood, 
lymphadenopaty, hepatosplenomegaly, high LDH in 
AML patient. 
Cytology 
Positive for CD 34, HLDR, CD33, CD68, MPO in 
AML. 
Treatment 
Chemotherapy followed by bone marrow 
transplantation in AML. 
Evolution 
After the first cycle of therapy, persistent bone marrow 
infiltration with 11% blasts. 
Prognosis 
Survival 6 month in MDS, 15 month+ in AML. 
Cytogenetics 
Cytogenetics morphological 
May be misinterpreted as t(3;5) in suboptimal 
preparations. 
Cytogenetics molecular 
FISH analysis is recommended to exclude the more 
frequent t(3;5). 
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FISH with WCP 3 and 4 and LSI BCL6 and 5q EGR1 probes. 
Probes 
WCP 3 and 4 probes, locus specific BCl6 and 5q 
probes. 
Additional anomalies 
t(3;4)(p21;q34) is part of a complex karyotype in MDS 
case associated with del(20q), sole abnormality in 
AML case. 
Genes involved and Proteins 
Note: 3p21 is a recurrent breakpoint in MDS/AML and 
t-MDS/t-AML suggesting, 3p21 site is likely to contain 
a gene (genes) involved in the pathogenesis of 
t(3;4)(p21;q34). Frequent deletion or allelic loss of 
band 3p21 is common in solid tumors, indicating the 
presence of tumor suppressor genes on this 
chromosome arm. The association among structural 
chromosome 3 aberrations and fragile sites on 3p may 
indicate the importance of previous mutagen exposure 
in the etiology of these diseases. 
Although several cancer-related genes have been 
located to 3p21, no gene has yet been identified to be 
related with hematological malignancies. One of the 
candidate genes may be the AF3p21 gene, a novel  
fusion partner of the MLL gene described in a patient  
who had developed therapy-related leukemia with 
t(3;11)(p21;q23). AF3p21 encodes a protein localized 
exclusively in the cell nucleus, suggesting the 
possibility that AF3p21 protein plays a role in signal 
transduction in the nucleus. 
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